Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Neoplasms 6Stomach Neoplasms 5Melanoma 5Carcinoma, Hepatocellular 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Solid Tumor 4Carcinoma, Transitional Cell 4Advanced Solid Tumors 4Small Cell Lung Carcinoma 3Sarcoma 3Nasopharyngeal Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Liver Neoplasms 2Liposarcoma 2Esophageal Squamous Cell Carcinoma 2Uterine Cervical Neoplasms 1Solid Tumor, Adult 1Solid Cancer 1Recurrence 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1

Interventions

pembrolizumab 40Cisplatin 25Fluorouracil 24Paclitaxel 21Oxaliplatin 16Capecitabine 12Leucovorin 10Irinotecan 10Docetaxel 10Gemcitabine 8Carboplatin 7atezolizumab 6Nivolumab 6Bevacizumab 6Trastuzumab 5Ramucirumab 5Radiotherapy 5spartalizumab 4Albumin-Bound Paclitaxel 4zanidatamab 3tisotumab vedotin 3patritumab deruxtecan 3lenvatinib 3fludarabine 3durvalumab 3Radiation 3Drug Therapy 3Cyclophosphamide 3130-nm albumin-bound paclitaxel 3zimberelimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Neoplasms × toripalimab × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡